Skip to main content
Clinical Trials/NCT05215197
NCT05215197
Recruiting
Not Applicable

Intracochlear Platelet-rich Fibrin Application in Cochlear Implantation

Pamukkale University1 site in 1 country10 target enrollmentJanuary 31, 2022

Overview

Phase
Not Applicable
Intervention
intracochlear platelet rich fibrin administration
Conditions
Hearing Loss, Sensorineural
Sponsor
Pamukkale University
Enrollment
10
Locations
1
Primary Endpoint
Electrode Impedance(Ohm)
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

Fibrosis due to surgical trauma is a common problem with cochlear implants. Fibrosis limits the effectiveness of implant and increases the power consumption. Our aim in this study is to benefit from the anti-inflammatory effects of autologous platelet-rich fibrin to reducing the fibrotic cascade.

Detailed Description

The most common problem with cochlear implants is that their effectiveness decreases over time and they are not functional enough mainly due to fibrosis. Our aim in this study is to benefit from the anti-inflammatory effects of autologous platelet-rich fibrin to reducing the fibrotic cascade. Cochlear implant application will be performed under general anesthesia. After the postauricular incision and mastoidectomy, posterior tympanotomy will find the middle ear and from there the round window, and platelet fibrin prepared with the i-prf technique will be locally applied to the round window during the operation, and then implantation will be performed. The points where the electrode enters the cochlea will be covered with fascia. Intraoperative NRT and impedances will be measured on all electrodes in all patients, and NRT and impedance measurements will be repeated in the 1st week, 1st month, 3rd and 6th months postoperatively. Custom Sound EP 5.0 (5.0.4.136) program provided by Cochlear company will be used for these measurements.

Registry
clinicaltrials.gov
Start Date
January 31, 2022
End Date
December 20, 2025
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Fazıl Necdet Ardıç

Head of Department of Otolaryngology

Pamukkale University

Eligibility Criteria

Inclusion Criteria

  • Patients with sensorineural hearing loss
  • Patients who will have cochlear implant surgery with CI422 electrode

Exclusion Criteria

  • Patients with cochlear abnormality
  • Patients with auditory neuropathy

Arms & Interventions

intracochlear prf administration group

intracochlear prf administration group

Intervention: intracochlear platelet rich fibrin administration

Outcomes

Primary Outcomes

Electrode Impedance(Ohm)

Time Frame: 1-6 months

All intra-operative impedance values will be acquired after surgery. They will be repeated in first week, 1, 3 and 6th months

Secondary Outcomes

  • Electrode thresholds(CL)(1-6 months)

Study Sites (1)

Loading locations...

Similar Trials